الوصف

Cell proliferation assay results comparing melatonin-treated and control prostate cancer cells. MLT treatment appears to inhibit proliferation in both 22RV1 and C4-2 cell lines.

Figure 5

Chart

Source Paper

Melatonin inhibits lipid accumulation to repress prostate cancer progression by mediating the epigenetic modification of CES1.

Clinical and translational medicine (2021)

PMID: 34185414

DOI: 10.1002/ctm2.449

Cite This Figure

![Figure 5: Cell proliferation assay results comparing melatonin-treated and control prostate cancer cells. MLT treatment appears to inhibit proliferation in both 22RV1 and C4-2 cell lines.]()

> Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." *Clinical and translational medicine*, 2021. PMID: [34185414](https://pubmed.ncbi.nlm.nih.gov/34185414/)

<figure>
  <img src="" alt="Cell proliferation assay results comparing melatonin-treated and control prostate cancer cells. MLT treatment appears to inhibit proliferation in both 22RV1 and C4-2 cell lines." />
  <figcaption>Figure 5. Cell proliferation assay results comparing melatonin-treated and control prostate cancer cells. MLT treatment appears to inhibit proliferation in both 22RV1 and C4-2 cell lines.<br>  Source: Lijie Zhou et al. "Melatonin inhibits lipid accumulation to repress prostate cancer progression by ." <em>Clinical and translational medicine</em>, 2021. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/34185414/">34185414</a></figcaption>
</figure>

أدلة ذات صلة

Melatonin لـ اضطراب الإيقاع اليوماوي

التقييم A · 176 دراسات